Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov;17(6):1427-1432.
doi: 10.1177/19322968231170884. Epub 2023 Apr 27.

Evidence and Diabetes Technology: A Catch-22?

Norbert Hermanns  1 , Bernd Kulzer  1 , David C Klonoff  2 , Lutz Heinemann  3
Affiliations
Editorial

Evidence and Diabetes Technology: A Catch-22?

Norbert Hermanns et al. J Diabetes Sci Technol. 2023 Nov.

Abstract

Diabetes technology is a dynamically evolving field. Sometimes the pace of evaluation of new diabetes technologies does not keep pace with its dynamic development. This leads to a dilemma: either the evaluation lags behind the developing technologies or diabetes technologies are used without sufficient evaluation. This situation is known as the Catch 22 dilemma. The aim of this paper is a discussion of ideas for a timely assessment, taking account of the speed of technological development and the need for evidence and safety improvement.

Keywords: CGM systems; diabetes technology; evidence; glucose monitoring; insulin pens.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: NH is member of the advisory board for Insulet, Research support from Roche Diagnostics, Sanofi, EmbectaBK is a member of the advisory board of Roche Diabetes Care, Sanofi-Aventis, NovoNordisk, Berlin Chemie, BD and Insulet. He received speaker honoraria from Roche Diabetes Care, Sanofi-Aventis, NovoNordisk, Berlin Chemie, Decxom, BD, Abbott Diabetes Care and Insulet.DCK is a consultant for EOFlow, Integrity, Lifecare, and Thirdwayv.LH is a consultant for several companies that are developing novel diagnostic and therapeutic options for diabetes treatment. He is a shareholder of the Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.

References

    1. Lee I, Probst D, Klonoff D, Sode K. Continuous glucose monitoring systems: current status and future perspectives of the flagship technologies in biosensor research. Biosens Bioelectron. 2021;181:113054. doi:10.1016/j.bios.2021.113054. - DOI - PubMed
    1. Nimri R, Nir J, Phillip M. Insulin pump therapy. Am J Ther. 2020;27(1):e30-e41. doi:10.1097/MJT.0000000000001097. - DOI - PubMed
    1. Klonoff DC, Kerr D. Smart pens will improve insulin therapy. J Diabetes Sci Technol. 2018;12(3):551-553. doi:10.1177/1932296818759845. - DOI - PMC - PubMed
    1. Klonoff DC, Gutierrez A, Fleming A, Kerr D. Real-world evidence should be used in regulatory decisions about new pharmaceutical and medical device products for diabetes. J Diabetes Sci Technol. 2019;13(6):995-1000. doi:10.1177/1932296819839996. - DOI - PMC - PubMed
    1. Center for Biologics Evaluation and Research (CBER). Guidance for industry non-inferiority clinical trials. Draft Guidance. 2010. https://www.fdanews.com/ext/resources/files/archives/n/NoninferiorityGui....

Publication types